Abstracts Submission

DEADLINE: 1^st MARCH 2027

INSTRUCTIONS FOR AUTHORS

The Scientific Committee of the 26th ESVOT Congress invites authors to submit scientific abstracts for podium and poster presentation at the Congress. These should be of original and unpublished work. Papers from practitioners are particularly welcome.
A maximum of two papers per author will be accepted.

Free communications to be presented in the Main scientific session will be evaluated by the scientific committee and those pertinent to the topics of the Congress will be favoured.

Free Communications must be written and presented in English.

Abstracts about the 2027 main topic “Feline Orthopaedics” are favoured.

Oral presentations have a 20-minute slot (including 5 min for questions/answers) which may not be exceeded. Abstracts should report recent clinical research; preliminary findings and single case reports will be also considered. Research abstracts must have ethical review approval if needed. Additionally, research must not have been published nor accepted for publication by the closing date of submission 1st MARCH 2027, 11:59 PM (Rome Time Zone).

All abstracts are reviewed by the Congress Scientific Committee, which reserves the right to select abstracts relevant to the sessions and topics and decides on the final form of the presentation (oral or poster) and on publication.

Authors are required to upload a long abstract for the Scientific Committee review and short version for publication on the book of proceedings (max 250 words).

Posters related to recent research into any aspect of veterinary orthopaedics and traumatology will be accepted for evaluation by the Scientific Committee.

Once the review process of all submitted abstracts is completed, authors will receive an e-mail informing whether the abstract has been accepted and whether it has been selected for poster or for oral presentation.

All abstract presenters (first author) must register for the Congress and are granted a 30% reduction on the Congress registration fee. Submitted abstracts will be accepted and published in the conference proceedings only upon receipt of payment.

ABSTRACTS ARE TO BE SUBMITTED ONLINE BY 1st MARCH 2027, 11:59 PM (Rome Time Zone).

Authors whose abstracts have been accepted will be notified latest by 15th April, 2027.

For abstract submission please go to the ABSTRACT SUBMISSION CENTRE at web site http://abstract.evsrl.it/
To access the ABSTRACT SUBMISSION CENTRE it is necessary to get a user name and a password for the EGO System.
Should you do not have user name and password, please go to EGO Home Page at http://ego.evsrl.it/.
Username and password will be sent in 2 working days.

The ABSTRACT SUBMISSION CENTRE will guide you filling up the following fields:

1. ABSTRACT
   A single abstract is required: text length should be max. 6.000 characters including spaces for the long abstract and an additional short abstract for publication (max. 250 words).
2. TITLE
   Title of work must be in CAPITAL LETTER, maximum length 180 characters including spaces.
3. SUBJECT
4. ADDRESS FOR CORRESPONDENCE
5. AUTHORS
   Max. 7 authors. Mark the presenting author with an asterisk.
   Indicate affiliation to an institute with superscript numbering e.g. Smith T1, Patterson C2.
   Enter institutes in numerical sequence after the parameter e.g.
   1 XXXXXX, 2XXXXXX
6. TEXT AND BIBLIOGRAPHY
7. DISCLOSURE STATEMENT*
   A conflict of interest statement and/or an involvement (or better financial interest) with products used in the study needs to be stated at abstract submission and should be displayed during the lecture as second slide
8. ETHICAL APPROVAL if applicable
9. SHORT ABSTRACT FOR PROCEEDINGS (MAX 250 WORDS)

* Disclosure Statement

To ensure transparency and maintain the scientific integrity of the Congress, all abstract presenters are required to submit a disclosure statement on behalf of all co-authors at the time of abstract submission.

The purpose of this statement is to allow Congress participants to identify any actual or potential conflicts of interest, including circumstances that could give rise to a perception of bias.

A conflict of interest may arise when an author, or an individual closely associated with an author (such as a family member, spouse, or friend), has a direct or indirect relationship with an organisation or entity that may have an interest in the work being presented.

Disclosures should include, but are not limited to, the following:

• Support for the submitted study: Any financial or non-financial support received in connection with the research described in the abstract.
• Support for other activities: Any financial or non-financial support received for other research projects or professional activities involving the authors, even if unrelated to the submitted abstract.
• Financial relationships: Any financial interests or benefits received by an author or a related individual, whether or not directly connected to the subject of the abstract. These may include salaries, royalties, consultancy fees, speaker honoraria, ownership interests (such as shares or stock options), or other forms of compensation.
• Indirect benefits: Any circumstances in which an author or their institution may benefit from the findings or outcomes of the study. For example, this may apply when an author or their institution operates a laboratory providing a diagnostic test or service discussed in the abstract.

Failure to disclose a relevant conflict of interest may result in the rejection of the abstract and/or restrictions on submitting abstracts to future Congresses.

How to Submit Your Disclosure Statement

Authors are strongly encouraged to follow the principle of full disclosure. When uncertain whether a relationship or interest should be declared, it is advisable to include it. The Congress Committee will review the information provided and determine whether disclosure is necessary.

Please use the designated text box in the abstract submission form to provide the following information:

• The name(s) of the author(s) concerned.
• The name of the commercial organisation or entity involved.
• A clear description of the nature of the relationship or potential conflict of interest.

Mandatory Disclosure Slide for Presentations

All speakers must include a disclosure statement on the second slide of their presentation, immediately following the title slide.

This requirement applies to all speakers and is intended to ensure transparency for the Congress audience.